



“The case isn’t finished until it is “SUTURE-TIGHT”™”

\$16M Series B preferred equity to fund FDA 510k 100 patient pivotal trial, only 12 mos. follow up

Raised \$12.8M

Post Series A valuation \$17.2M

Joseph Rafferty CEO
J.Rafferty@VESTECK.COM
610-457-7324



VESTECK
INC.

“The case isn’t finished until it is “SUTURE-TIGHT”™”

The “Suture-Tight”™ catheter is a platform technology, comes preloaded with 4 nitinol sutures for use in aortic repair, structural heart, peripheral and venous applications.




Why have Medtronic, Boston Sci and Sofinnova made recent investments in the aortic repair market?

- **Big profitable aortic repair market**
 - Large Baby Boomer population entering peak of aortic disease
 - Well documented global EVAR/TEVAR durability problem
- **MDT rejuvenating aortic repair business**
 - Funding new 3 studies ~1,000 patients (\$200M?)
- **BSX second investment as Nectero validates aortic biology**
 - Aortic tissue transitions from elastin to collagen
 - Aorta will dilate regardless of graft implanted
- **Sofinnova two investments in aortic repair space**

PROBLEM: EVAR/TEVAR NOT DURABLE AORTIC ANEURYSM PATIENTS HAVE TWO THERAPEUTIC OPTIONS


Open Surgical Repair



Open Surgical Repair is durable but carries a high mortality rate

- **4.8%** perioperative mortality
- **19.2%** in high risk patients ^{1,2,3}

Endovascular Repair (EVAR/TEVAR)





~80% of patients and physicians select an endovascular approach


EVAR/TEVAR IS NOT DURABLE ^{1,2}

- **1.2%** perioperative mortality
- **4.7%** in high risk patients ^{1,2,3}






'Suture-Tight' pre-loaded with 4 pair of nitinol sutures. Speed of EVAR, durability of Open Surgical Repair



“SUTURE-TIGHT” over the wire catheter delivers sutures that can be repositioned, at initial graft implant or during repair procedures




Vesteck's *Suture-Tight* catheter secures the graft to the adventitia the strongest part of the aorta







Suture-Tight Case Example


- Case conducted at Prince of Wales in Australia under FIH clinical study (sponsored by Vesteck, Pr. Ramon Varcoe as PI)
- 68 yo male
- AAA: 51mm sac, 17/22 mm neck length/diameter
- Elective EVAR with Gore Excluder
- 4 Suture-Tight Sutures placed in 4 quadrants
- Total time of Suture-Tight procedure was 12 minutes (using both right then left femoral access)
- Same Surgeon previous case, 4 minutes, 4 sutures delivered




Suture Deployment



Follow-up Imaging (L-R: 40°)




1 Month




6 Months

Follow-up Imaging (L-R: -57°)

1 Month



6 Months





Device works! 14 successful clinical cases completed

8 Different Physician implanters in Canada, Europe, Australia

FIH Case No.	Procedure Date	MD Operator	SAB Member Present	Commercially Available Endograft Placed	Major Adverse Events (MAEs)	Migration	Leaks	Suture fracture or embolization	Case Location
1	23-Feb-2023	Krievins	Yamanouchi	Yes	No	No	No	No	Latvia (CLP-03 FIH Study)
2	23-Feb-2023	Krievins	Yamanouchi	Yes	No	No	No	No	Latvia (CLP-03 FIH Study)
3	8-Mar-2023	Bui	Lyden	Yes	No	No	No	No	Canada (Special Access Program)
4	31-Mar-2023	Bui	Ramaiah	Yes	No	No	No	No	Canada (Special Access Program)
5	31-Mar-2023	Bui	Ramaiah	Yes	No	No	No	No	Canada (Special Access Program)
6	23-May-2023	Krievins	Bui	Yes	No	No	No	No	Latvia (CLP-03 FIH Study)
7	23-May-2023	Krievins	Bui	Yes	No	No	No	No	Latvia (CLP-03 FIH Study)
8	11-Nov-2023	Krievins	-	Yes	No	No	No	No	Latvia (CLP-03 FIH Study)
9	11-Nov-2023	Krievins	-	Yes	No	No	No	No	Latvia (CLP-03 FIH Study)
10	18-Dec-2023	Varcoe	Holden	Yes	No	No	No	No	Australia (CLP-05 FIH Study)
11	19-Dec-2023	Thomas	Varcoe	Yes	No	No	No	No	Australia (CLP-05 FIH Study)
12	19-Dec-2023	Thomas	Varcoe	Yes	No	No	No	No	Australia (CLP-05 FIH Study)
13	23-Feb-2024	Bui	Ramaiah	Yes	No	No	No	No	Canada (Special Access Program)
14	23-Feb-2024	Bui	Ramaiah	Yes	No	No	No	No	Canada (Special Access Program)

“TECHNOLOGY SIGNIFICANTLY DERISKED”

- **14 clinical cases successfully completed, 6 and 12 months out**
- **KOL’s in alignment. “will become the standard of care for all EVAR/TEVAR.”**
 - speaking at global meetings VIVA, VEITH, CHARRING CROSS, ISET, TED, GREENBERG STENT
- **Clear FDA 510K regulatory pathway, only 100 patients, 1 year follow up**
 - 5 Pre-sub meetings, IDE reviewed
- **Existing DRG/CPT reimbursements for initial implant and repair procedures**
- **“SUTURE-TIGHT System” 3 new issued patents, 2 more filed, 2 existing**
 - US, Canada, AU, NZ, EU, UK, China, Japan, On the way in India.
- **Australia LLC formed**
 - leverage currency exchange and 43.7% R&D investment rebate, will conduct 50% of clinical trial in A

\$4.8 B Global Aortic Repair Market by 2028 ^{14, 15}

Initially targeting very 2 large markets


Initial implant EVAR/TEVAR

- >3M global patients with abdominal and thoracic aneurysms
- >400,000 global patients diagnosed and monitored
- >125,000 globally AAA/TAA procedures performed

Repair procedures ~1 M patients with failing implants


- 5-year EVAR re-intervention rate 21% (TEVAR is higher.)

Will bring an incremental \$700 M at 50% Global TAM




VESTECK platform device, aortic, structural heart, peripheral, venous, GI

1. TAVR, Structural Heart for Perivalvular leak
2. TEVAR, arch to descending thoracic aortic implant/repair
3. EVAR/FEVAR/BEVAR device abdominal aneurysms
4. Secure graft to graft revision procedures
5. Specialty sutures to repair "Type 1A Endoleaks"
6. Iliac device for securing bifurcation limbs
7. Venous stent security, May Thurner Syndrome
8. Integrated EVAR/TEVAR graft and suture delivery catheter
9. Device capable of delivering 3-4 sutures simultaneously




Platform technology, today and the future



TODAY



Multiple Suture Simultaneous Delivery



VESTECK, Inc. GRAFT RETENTION MECHANISM

Market Modeling as a “tuck in” for an existing sales team

	Market Share	2027	2028	2029	2030	2031
US AAA TAM		127,642	132,573	137,746	143,173	148,865
DeNovo and Repair	20%	\$ 127,642,249	\$ 132,573,499	\$ 137,746,380	\$ 143,172,732	\$ 148,864,975
	30%	\$ 191,463,373	\$ 198,860,248	\$ 206,619,569	\$ 214,759,097	\$ 223,297,462
	40%	\$ 255,284,498	\$ 265,146,997	\$ 275,492,759	\$ 286,345,463	\$ 297,729,950
	50%	\$ 319,105,622	\$ 331,433,747	\$ 344,365,949	\$ 357,931,829	\$ 372,162,437

	Market share	2027	2028	2029	2030	2031
Global TEVAR	20%	\$ 8,418,068	\$ 8,830,553	\$ 9,263,250	\$ 9,717,149	\$ 10,193,290
DeNovo	30%	\$ 12,627,101	\$ 13,245,829	\$ 13,894,875	\$ 14,575,724	\$ 15,289,934
-	40%	\$ 16,836,135	\$ 17,661,106	\$ 18,526,500	\$ 19,434,299	\$ 20,386,579
-	50%	\$ 21,045,169	\$ 22,076,382	\$ 23,158,125	\$ 24,292,873	\$ 25,483,224
-						
Global	Market share	2027	2028	2029	2030	2031
DeNovo and Redo	20%	\$ 255,284,498	\$ 265,146,997	\$ 275,492,759	\$ 286,345,463	\$ 297,729,950
EVAR	30%	\$ 382,926,747	\$ 397,720,496	\$ 413,239,139	\$ 429,518,195	\$ 446,594,925
-	40%	\$ 510,568,996	\$ 530,293,994	\$ 550,985,518	\$ 572,690,927	\$ 595,459,900
-	50%	\$ 638,211,245	\$ 662,867,493	\$ 688,731,898	\$ 715,863,658	\$ 744,324,875
-						
Global EVAR/TEVAR	Market share	2027	2028	2029	2030	2031
-	20%	\$ 263,702,565	\$ 273,977,550	\$ 284,756,009	\$ 296,062,613	\$ 307,923,240
	30%	\$ 395,553,848	\$ 410,966,325	\$ 427,134,014	\$ 444,093,919	\$ 461,884,859
	40%	\$ 527,405,131	\$ 547,955,100	\$ 569,512,018	\$ 592,125,225	\$ 615,846,479
	50%	\$ 659,256,414	\$ 684,943,875	\$ 711,890,023	\$ 740,156,531	\$ 769,808,099

Competition:

Medtronic Heli-FX

Repurposed hernia mesh tac

Commercially available, very challenging to use
System list price ~\$8,200, ASP ~\$6,000 10 sutures




“~30% Heli-FX are maldeployed and...not useful” ¹⁹



Not commercially available

A Sofinnova Portfolio Company



8 sutures delivered in one shot

-challenge with calcium, thrombus, hostile neck, angles

**“SUTURE-TIGHT” has
More clinical applications.**

**Designed by physicians to fit
smoothly into existing
procedural workflow.**



VESTECK Inc.

- ✓ Very easy to use- single insertion
- ✓ Safety- sutures preloaded virtually eliminate embolization
- ✓ Speed- faster suture delivery
- ✓ Accuracy-precise placement
- ✓ Durability- Nitinol shape memory

\$3,500 list price, \$2,500 ASP catheter preloaded with 4 sutures.
\$5,000 – gross revenue per patient.
15% cost of parts/labor

Endovascular/Peripheral M&A Recent Acquisitions

- \$415M Inari acquires LimbFlow (recent FDA, \$0 revenue)
- \$360M Endologix acquires PQ bypass (pre FDA, \$0 revenue)
- \$890M Abbott acquires CSI (\$36.9M loss)
- \$370M Boston Scientific acquires Devoro, clot removal(pre FDA \$0 revenue)
- \$360M Phillips acquires InTact, spot stent (\$125M invested<\$50M revenue)
- \$340M Edwards acquires Valtech's repair of tricuspid +mitral valves
- \$280M Terumo acquires Sequent Web's Embolization System
- \$270M Boston Scientific acquires Claret Medical (<\$20M revenue)
- \$230M SpectraNetics acquires Angioscore
- \$110M Medtronic acquires Aptus Medical *2015*
- \$225M CryoLife acquires Jotec GmbH

“VESTECK will become the standard of care for every EVAR/TEVAR patient.”

David H Deaton MD, Vascular Surgeon, Former Chief, Vascular Surgery Georgetown, former APTUS CMO



Global Key Opinion Leaders are in alignment

When asked about the patient benefits of the VESTECK, “SUTURE-TIGHT”™ catheter technology SAB member Professor Michel Reijnen said,



“After >25 years of performing EVAR procedures we are still encountering the same problems as in the past...leaks and migration.

We therefore **we need novel solutions**, adding different technologies to EVAR, in order to make the treatment more effective and durable.”

KOL'S "SUTURE-TIGHT" *"for initial implant and repair"*



"We are in need of additional tools like this to help our EVAR/TEVAR patients."

Sean Lyden MD, Vascular Surgeon, Chairman Department of Vascular Surgery Cleveland Clinic, OH



"I'll use VESTECK even in patients who are within the IFU and have increased risk of proximal failure." Daniel Clair MD, Chairman Dept. Vascular Surgery Vanderbilt University Medical Center, TN



"VESTECK, SUTURE-TIGHT is a tool that interventionalists need now."

Peter Schneider MD, Vascular Surgeon, University San Francisco



"I will allow MLH physicians to use "SUTURE-TIGHT" we can't predict which patient's aortas will dilate. So, with an easy to use, safe, fast, inexpensive system like this...."

William Gray MD, Interventional Cardiologist, Cardiovascular System Chief Main Line Health, Phila. PA



"Fits easily into my EVAR/TEVAR procedural workflow right away."

Venkatesh Ramaiah MD, Chief/Network Director Complex Vascular Services Honor Health Phoenix AZ

Global Scientific Advisory Board



Dr. Sean Lyden

VESTECK CMO

Chair of the Department of Vascular
Surgery Cleveland Clinic



Dr. Venkatesh Ramaiah

Honor Health Chief
Network Director, Complex Vascular
Services



Prof. Ramon Varcoe

Director of Surgery Sydney AU



Dr. Daniel Clair

Chair Dept of Vascular Surgery
Vanderbilt University



Dr. Dai Yamanouchi

Chair, Department of Vascular Surgery Fujita
University Hospitals Japan



Dr. William Gray

System Chief Division of Cardiovascular
Disease at Main Line Health, PA



Dr. Sukgu Han

Chief Div. Vascular
Surgery/Endovascular Therapy
USC



Prof. Andrew Holden

Director Northern Region
Interventional Radiology Service
New Zealand



Dr. David Deaton

Inroad Medical
Former Chief Medical Officer
of APTUS



Prof. Michel Reijnen

Endovascular Imaging and Innovation
University of Twente, Netherlands



Dr. Bao Bui

Endovascular Intervention
University Sherbrooke, Quebec CA



Prof. Dainis Krievins

Professor, Director: Institute of
Research of P. Stradins University
Hospital Latvia

Our M&A options have physician relationships and sales bags to tuck in

EVAR/TEVAR Graft companies



Peripheral companies w/relationships



Not available for sale in USA/OUS



Robert Mitchell Chairman of the Board of Directors



Joseph W. Rafferty CEO



Dr. John Edoga Founder



Dr. Thierry Richard Founder



Terrie Heidemann
Director Quality



Elisa Harvey DVM, PhD
Regulatory Consultant

Leadership: with deep endovascular market knowledge, execute and exit



Laura Lund, PhD
Director Clinical Strategy Consultant



Kent Stalker
COO, VP R&D



Dennis McGrath
Chief Financial Consultant
Treasurer




Ted Wulfman
Chief Technology Officer



Dorothy Abel
Regulatory Consultant

\$16M Series B will be used to fund 100 PT FDA 510K clearance

Culture of Milestone achievement





“The case isn’t finished until it is “SUTURE-TIGHT”™”

\$16M Series B preferred equity to fund 510k 100 patient/12 mos. follow up pivotal trial

Raised \$12.8M

Post Series A valuation \$17.2M

Joseph Rafferty CEO
J.Rafferty@VESTECK.COM
610-457-7324